The Human Variable 

The COVID-19 pandemic has added another layer of immune instability through persistent inflammation, viral reactivations, and population-wide biologic stress . CRATE™ converts these complex dynamics into actionable modeling signals to inform future prevention strategy

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

Bioadaptive Systems Therapeutics™ (BST) is a new discipline of medicine that engineers remission by recalibrating fragile biological systems across immune, autonomic, mitochondrial, connective, hormonal, and environmental domains. Unlike traditional medicine, which classifies disease onset and treats within rigid silos, BST is phase-aware, terrain-first, and subtype-specific.

Introduction Myalgic encephalomyelitis/chronic fatigue syndrome is common, costly, and routinely missed until someone reads the chart as a timeline. Patients describe a delayed crash after effort that lasts days to weeks. CDC and NICE name this pattern post-exertional malaise and make it central to diagnosis (CDC, 2024; NICE NG206, 2021). Yet most people with ME/CFS still do not have a diagnosis, and many wait years for recognition, with the National Academies reporting both

A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS. It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio

Contrary to the conventional framing of remission as spontaneous or unachievable, this framework presents remission as a predictable biological outcome, emerging from synchronized interventions across immune, hormonal, mitochondrial, and environmental axes. The CYNAERA Remission Pathway™ outlines a five-phase stabilization and recovery model, while the STAIR: Stable Method™ offers pre-intervention protection for hypersensitive subgroups, including those with mast cell reacti